Silvio Gutkind, PhD of University of California San Diego discusses recent data presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The data presented comes from a preclinical trial investigating Verastem Oncology’s FAK inhibitor (defactinib) and RAF-MEK inhibitor (VS-6766) for uveal melanoma. 

Uveal melanoma is a rare cancer; however, it is the most prevalent cancer of the eye in adults. The ten-year survival rate is approximately 50% and in approximately half the cases, the cancer metastasizes to the liver.  Currently, there is no FDA-approved treatment for uveal melanoma.

Results from the preclinical study are positive, with current data suggesting that the combination of defactinib and VS-6766 as a promising treatment option for uveal melanoma.

For more information on uveal melanoma and other rare cancers, visit


  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.